| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Pyxis Oncology, Inc. (PYXS) has 0 insiders with recent SEC Form 4 filings, including 4 buys and 1 sell. PYXS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21, 2022 | Chin Mark | Former Director | Sell | 1,745,761 | $3.05 | $5,324,571.05 | -100% | +6.4% | +24.9% | |
| Dec 8, 2021 | Cline Darren S | Director | Buy | 10,000 | $9.39 | $93,885.00 | New | -51.8% | -87.3% | |
| Nov 18, 2021 | Civik Thomas | Director | Buy | 15,700 | $12.74 | $200,018.00 | New | -39.1% | -89.3% | |
| Oct 13, 2021 | Cormorant Asset Management, LP49 | Former 10% Owner | Buy | 450,000 | $16.00 | $7,200,000.00 | +67.3% | -12.4% | -86.3% | |
| Oct 13, 2021 | Chin Mark | Director | Buy | 312,500 | $16.00 | $5,000,000.00 | +21.8% | -12.4% | -86.3% |